Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT501 +/- Bortezomib in Multiple Myeloma
NCT00920556Phase 2Terminated
- Sponsor
- GSK
- Start
- Mar 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of SRT501 in multiple myeloma (MM), sponsored by GSK. Started Mar 2009; status: terminated.
02
Drugs
SRT501
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00920556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920556.